Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Revolution Medicines
Company

Revolution Medicines

Tracked across 1 events · 10 articles · First seen Apr 19, 2026 · Last active Apr 19, 2026

Sentiment
70
Attention
4
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Tech
Revolution Medicines Zoldonrasib Phase 1 Data
Revolution Medicines announced positive updated Phase 1 clinical data for zoldonrasib in patients with KRAS G12D non-small cell lung cancer. This strengthens the profile of zoldonrasib and supports its continued clinical development, potentially leading to significant market opportunities for Revolution Medicines.
Apr 19, 2026 · 10 articles
Key Actions (2)
100 Revolution Medicines announced updated Phase 1 clinical data for zoldonrasibRevolution Medicines...
80 Revolution Medicines presented data at American Association for Cancer Research Annual Meeting American Association for Cancer ResearchRevolution Medicines...
Relationships (2)
Jonathan Riess principal investigator ↔ Revolution Medicines Jonathan Riess is the principal investigator for Revolution Medicines' RMC-9805-
Alan Sandler chief development officer ↔ Revolution Medicines Alan Sandler is the chief development officer of Revolution Medicines.
NEWSDESK
Track Revolution Medicines live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.